Cargando…
Orphan patients with inflammatory bowel disease - when we treat beyond evidence
Inflammatory bowel disease (IBD) is a chronic condition that requires continuous medical treatment. To date, the medical management of patients with moderately-to-severely active IBD who develop dependence or resistance to corticosteroids is based on immunomodulator drugs. Such therapies are licence...
Autores principales: | Privitera, Giuseppe, Pugliese, Daniela, Lopetuso, Loris Riccardo, Scaldaferri, Franco, Papa, Alfredo, Rapaccini, Gian Lodovico, Gasbarrini, Antonio, Armuzzi, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704270/ https://www.ncbi.nlm.nih.gov/pubmed/35068853 http://dx.doi.org/10.3748/wjg.v27.i47.8047 |
Ejemplares similares
-
Can We Predict the Efficacy of Anti-TNF-α Agents?
por: Lopetuso, Loris Riccardo, et al.
Publicado: (2017) -
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
por: Privitera, Giuseppe, et al.
Publicado: (2021) -
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre
por: Scaldaferri, Franco, et al.
Publicado: (2020) -
Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver
por: Lopetuso, Loris Riccardo, et al.
Publicado: (2018) -
Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
por: Privitera, Giuseppe, et al.
Publicado: (2021)